Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs United Airlines Holdings Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B), while United Airlines Holdings Inc trades at $105.64 (market cap $34.87B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and United Airlines Holdings Inc for 46 Days on average.
| TAK | UAL | |
|---|---|---|
Market Cap | $58.74B | $34.87B |
Volume | 3,110,994 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $19.05 | $136.11 |
52-Week Low | $13.23 | $85.21 |
Typical Hold Time | 1 Days | 46 Days |
Enterprise Value | $86.65B | $51.90B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
United Airlines (UAL) trades at $105.65, down 4.1% today, with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with revenue growth from $57.1B in 2024 to $59.1B in 2025 and net income of $3.35B. Valuation metrics appear attractive with P/E of 10.06 and P/S of 0.56. Recent news highlights aggressive customer acquisition strategies targeting Delta and American Airlines' premium travelers with status-match offers and Starlink-enabled WiFi advantages.
The investment outlook remains positive given strong analyst consensus (66% buy rating) with $158.10 price target representing 50% upside. Key risks include rising fuel costs, labor expenses, and competitive pressures. Earnings momentum continues with three consecutive quarterly beats, though Q3 2026 results will be crucial for maintaining investor confidence amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
